RCT: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer - results from the GETUG-AFU 15 study

Source: Lancet Oncology Area: News According to a study published early online in the Lancet Oncology, docetaxel should not be used as part of first-line treatment for patients with non-castrate metastatic prostate cancer.   Researchers conducted the phase III study to investigate the effects of the addition of docetaxel to androgen-deprivation therapy (ADT) for patients with metastatic non-castrate prostate cancer. The phase III open-label study involved 385 patients aged over 18 years and with histologically confirmed adenocarcinoma of the prostate and radiologically proven metastatic disease, a Karnofsky score of at least 70%, a life expectancy of at least 3 months, and adequate hepatic, haematological, and renal function. Patients were randomised to receive ADT (orchiectomy or luteinising hormone-releasing hormone agonists, alone or combined with non-steroidal anti-androgens, n=193) alone or in combination with docetaxel 75 mg/m2 intravenously on the first day of each 21-day cycle, for up to nine ...
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news